- Version 1.0
- Download 5
- File Size 764 MB
- File Count 1
- Create Date September 29, 2025
- Last Updated October 28, 2025
Harnessing ctDNA-MRD to Guide Complex Treatment Decisions in Advanced HER2+ Breast Cancer
In this compelling presentation, Dr. Samuel J. Haryono shares the real-world journey of a young woman with recurrent, high-risk HER2-positive breast cancer, illustrating how K-TRACK™ ctDNA-MRD transformed her care pathway. Faced with multiple recurrences over nearly a decade—and at times inconclusive results from imaging and tumor markers—serial ctDNA testing provided the clarity needed to act decisively.
Dr. Samuel details how an initial MRD-positive result (VAF 3.25%) prompted early detection of a small brain metastasis and a proactive switch to second-line HER2-targeted therapy (T-DM1), well before overt systemic progression. Subsequent MRD clearance validated treatment efficacy, while continued surveillance with ctDNA guided ongoing management. Even when conventional diagnostics showed no signs of relapse, ctDNA results offered critical molecular insights that shaped both escalation and continuation of therapy.
Through this case, Dr. Samuel demonstrates ctDNA-MRD’s potential to risk-stratify, monitor response, and detect recurrence earlier than standard tools—empowering oncologists to deliver more precise, timely interventions for patients with aggressive disease.
